Displaying 28 (all) recruiting clinical trials.
-
A Phase 1a/1b Study of LY3537982 in Patients with KRAS G12C-Mutant Advanced Solid Tumors
The purpose of the study is to determine and evaluate the safety, tolerability, and preliminary efficacy of oral LY3537982 as monotherapy and as part of ... -
A Phase 1b First-in-human Dose Escalation and Expansion Multicenter Study of XMT-1660 in Participants with Solid Tumors
If you are diagnosed with stage 4 tumor of any solid origin, for example; breast, endometrial, ovarian, fallopian tube, cervix, vaginal or primary peritoneal cancer ...
-
A Phase 1/1b Open-label Multicenter Study to Investigate the Safety Tolerability Pharmacokinetics and Antitumor Activity of KIN-2787 in Participants with BRAF and/or NRAS Mutation-positive Solid Tumors.
You can participate in this study if you are diagnosed with stage 3 or stage 4 skin melanoma. The purpose of this study is to ... -
A Phase 1 Open-Label Multicenter Study to Assess Safety Tolerability PK and Efficacy of MK-1084 as Monotherapy and in Combination With Pembrolizumab in Subjects with KRASG12C Mutant Advanced Solid Tumors
You can participate in this study if you are diagnosed with any of the advanced solid tumors found in any of the organ systems. The ... -
A PHASE 1 STUDY OF TJ033721 IN SUBJECTS WITH ADVANCED OR METASTATIC SOLID TUMORS.
You can participate in this study if you are diagnosed with advanced solid tumors. The purpose of this study is to test the safety of ... -
A phase 1 study of SGN-BB228 in advanced melanoma and other solid tumors
You may qualify for this study if you have metastatic or unresectable melanoma or other advanced solid tumors. This study will include three phases: a ...
-
An Open-Label Multicenter Phase 1a Study of AN2025 and AN0025 in Double Combination with Atezolizumab and in Triple Combination with Atezolizumab in Patients with Advanced Solid Tumors.
You can participate in this study if you are diagnosed with advanced solid tumors. The purpose of this study is to assess the Safety, Tolerability ... -
A Phase I Open-label Multi-center Clinical Study to Evaluate Safety Tolerability Pharmacokinetics Pharmacodynamics and Preliminary Anti-Tumor Activity of AC176 in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) Who Have Progressed on at Least Two Prior Systemic Therapies
This study is designed for patients diagnosed with metastatic castration resistant prostate cancer (mCRPC).
This is a Phase I, first-in-human, open-label, multi-center dose-escalation study of ...
-
A Phase 1/1b Dose Escalation/Expansion Study of NGM831 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors
This study is designed for patients diagnosed with Advanced or Metastatic Solid Tumors.
For Part 1A, this study will assess the safety and tolerability at ...
-
A Phase 1 Dose-escalation and Expansion Study of the PD-1 x ILT4 Bispecific Antibody CDX-585 in Patients with Advanced Malignancies
This is a study to test a new medicine called CDX-585 on patients with advanced or spreading solid tumors that have not improved with current ...